BNP Paribas Financial Markets
AVBP icon

BNP Paribas Financial Markets’s ArriVent BioPharma AVBP Stock Holding History

BNP Paribas Financial Markets’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$388K Buy
11,170
+1,594
+17% +$47K ﹤0.01% 3893
2026
Q1 		$221K Buy
9,576
+4,103
+75% +$92.7K ﹤0.01% 4003
2025
Q4 		$110K Sell
5,473
-36,795
-87% -$766K ﹤0.01% 4332
2025
Q3 		$780K Buy
42,268
+39,697
+1,544% +$780K ﹤0.01% 3297
2025
Q2 		$56K Buy
2,571
+609
+31% +$12.6K ﹤0.01% 4218
2025
Q1 		$36.3K Sell
1,962
-1,338
-41% -$32.7K ﹤0.01% 4383
2024
Q4 		$87.9K Sell
3,300
-18,665
-85% -$536K ﹤0.01% 4203
2024
Q3 		$516K Buy
21,965
+5,397
+33% +$123K ﹤0.01% 2843
2024
Q2 		$307K Buy
16,568
+11,909
+256% +$212K ﹤0.01% 2909
2024
Q1 		$83.2K Buy
+4,659
New +$94K ﹤0.01% 3482

Other funds holding AVBP

HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BNP Paribas Financial Markets's AVBP Position: Q2 2026 in Review

BNP Paribas Financial Markets increased its ArriVent BioPharma (AVBP) stake by 17% in Q2 2026, buying an estimated $47K and bringing the position to 11,170 shares worth $388K. The position accounts for ﹤0.01% of the portfolio, ranked #3893.

BNP Paribas Financial Markets first reported a position in AVBP in Q1 2024 and has held it in 10 quarters since. The position peaked at $780K in Q3 2025. 141 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • BNP Paribas Financial Markets held 11,170 shares of ArriVent BioPharma worth $388K as of Q2 2026.
  • BNP Paribas Financial Markets bought 1,594 ArriVent BioPharma shares in Q2 2026, an estimated $47K.
  • ArriVent BioPharma made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #3893 holding.
  • BNP Paribas Financial Markets first reported a position in ArriVent BioPharma in Q1 2024 and has held it in 10 quarters since.
  • BNP Paribas Financial Markets's ArriVent BioPharma position peaked at $780K in Q3 2025.
  • 141 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.